Lyndra Therapeutics
Lyndra Therapeutics was a clinical-stage biopharmaceutical company that developed the proprietary LYNX drug delivery platform to transform daily oral medications into once-weekly or monthly therapies, with lead candidate LYN-005 (oral weekly risperidone) completing Phase 3 trials. The company collapsed in 2025 and sold its LYNX platform to Innoviva.
- Company typePrivate
- Founded2015
- HeadquartersWatertown, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lyndra Therapeutics does
Lyndra Therapeutics was a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, that developed long-acting oral medicines using its proprietary LYNX drug delivery platform. The LYNX platform was designed to transform standard daily oral medications into once-weekly or once-monthly formulations by providing stable dose release at target levels, thereby reducing side effects associated with peak-and-trough drug exposure and improving patient adherence through less frequent dosing. The company's lead product candidate was LYN-005, an investigational oral weekly formulation of risperidone for schizophrenia and other psychiatric conditions requiring long-term medication, which advanced through Phase 3 clinical trials with documented safety, tolerability, and dose release profiles across more than 100 human doses and 1,000 animal doses.
Lyndra operated under a licensing and partnership-driven business model rather than direct commercialization. In December 2023, the company granted Sun Pharmaceutical Industries an exclusive licensing agreement to manufacture and market three of its investigational oral weekly therapies in six countries including Brazil and India, targeting South American and Asia-Pacific markets. The company was backed by a syndicate of life-sciences-focused investors including Polaris Partners, Sarissa Capital, AIG Investments, Gilead Sciences, the Bill & Melinda Gates Foundation, and several Chinese and global healthcare funds, raising approximately $282 million cumulatively across at least seven funding rounds between 2016 and 2023.
Following the $101 million Series E financing in December 2023, the company was unable to sustain operations and ceased to function as an independent entity. In 2025, Innoviva, Inc. acquired the LYNX drug delivery platform for $10.2 million plus up to $20 million in milestones and royalties, transferring the technology to its wholly owned subsidiary Nortiva Bio. The collapse of Lyndra — despite Phase 3 clinical validation and a clinically differentiated technology — illustrates the capital intensity and execution risk inherent in clinical-stage drug delivery platforms seeking to bridge from validation to commercialization.
Lyndra Therapeutics firmographics
Firmographics- Name
- Lyndra Therapeutics
- Legal name
- Lyndra Therapeutics, Inc.
- Website
- https://lyndra.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Closed
- Headcount range
- 51–100 employees
- Short description
- Lyndra Therapeutics was a clinical-stage biopharmaceutical company that developed the proprietary LYNX drug delivery platform to transform daily oral medications into once-weekly or monthly therapies, with lead candidate LYN-005 (oral weekly risperidone) completing Phase 3 trials. The company collapsed in 2025 and sold its LYNX platform to Innoviva.
- Ownership category
- akta.pro rank
Lyndra Therapeutics industry classification
Industry- Product category
- Long-acting oral pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Prescription Digital Therapeutics (PDT) (HLACANAB)
Keywords
Where Lyndra Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Lyndra Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Distribution channels1 record
Lyndra Therapeutics product offering
Product offeringCore offering
Lyndra Therapeutics was a clinical-stage biopharmaceutical company developing long-acting oral medicines using its proprietary LYNX drug delivery platform, which transforms standard daily pills into once-weekly or monthly oral therapies with sustained drug release. The company's lead product candidate, LYN-005, was an investigational weekly oral formulation of risperidone for the treatment of schizophrenia and other psychiatric conditions requiring long-term medication.
Product overview
Lyndra Therapeutics was a clinical-stage biopharmaceutical company that developed a portfolio of oral weekly therapies enabled by its proprietary LYNX® drug delivery platform. The company's core product was LYN-005 (weekly oral risperidone), which was in late-stage phase 3 clinical trials. The technology transformed standard daily oral medications into sustained-release weekly or monthly formulations. Lyndra Therapeutics ceased operations and its LYNX platform was acquired by Innoviva in 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- LYNX Drug Delivery Platform
Quantifiable outcome
- 100+ doses administered in humans across clinical trials
- +2 more outcomes
Companies that use Lyndra Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Lyndra Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Lyndra Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Innoviva, Inc.coreAcquired the LYNX drug delivery platform from Lyndra Therapeutics for $10.2 million plus up to $20 million in milestones and royalties. The platform was then transferred to Nortiva Bio, Innoviva's wholly owned subsidiary.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
Lyndra Therapeutics competitors and assessment
Company assessmentDirect peers
- Tris Pharma: Tris Pharma is a specialty pharmaceutical company focused on long-acting, extended-release, and abuse-deterrent oral drug delivery technologies, making it the closest direct comparable to Lyndra's LYNX platform in mechanism, target customer profile (pharma partners), and formulation-led approach.
- Osmotica Pharmaceutical: Osmotica develops extended-release and specialty oral pharmaceutical products using proprietary osmotic and sustained-release delivery technologies. Comparable to Lyndra as a formulation-driven, long-acting oral therapeutics company targeting CNS and other chronic conditions.
- Heron Therapeutics: Heron develops long-acting specialty therapeutics using proprietary sustained-release and bioerodible polymer delivery technologies. Comparable to Lyndra in its mission of reducing dosing frequency for chronic conditions and its specialty-pharma commercial model, although Heron's products are injectable rather than oral.
Broad incumbents
- Catalent: Catalent is a global drug delivery and development services provider offering formulation, bioavailability-enhancement, and modified-release technologies for pharma partners. Comparable to Lyndra's underlying drug-delivery engineering capability, though Catalent operates as a broad CDMO serving many partners rather than a single-asset company.
- Otsuka Pharmaceutical: Otsuka is a major pharmaceutical company with a leading franchise in long-acting injectable antipsychotics (Abilify Maintena, Abilify Asimtufii, Aripiprazole Lauroxil). Comparable to Lyndra as the dominant incumbent alternative in the long-acting antipsychotic category that LYN-005 (weekly oral risperidone) targets.
- Johnson & Johnson: Johnson & Johnson markets Risperdal Consta (long-acting injectable risperidone) and other depot antipsychotic formulations, making it a direct therapeutic-area competitor to Lyndra's LYN-005 in the long-acting antipsychotic category, though J&J operates a much broader pharmaceutical portfolio.
- Teva Pharmaceutical: Teva has a substantial specialty and generics franchise with multiple extended-release oral products (including risperidone generics and other modified-release formulations). Comparable to Lyndra as a large-scale producer of long-acting oral therapeutics across CNS and other chronic indications.
- Pfizer CentreOne: Pfizer CentreOne is Pfizer's contract manufacturing and drug delivery services arm offering formulation development and modified-release capabilities to partners. Comparable to Lyndra's platform orientation toward pharma partners needing specialty oral delivery, though at a much broader scale.
Emerging players
- Eli Lilly: Lilly is advancing oral peptide and small-molecule drug delivery (e.g., orforglipron oral GLP-1) using novel formulation and permeation-enhancer technologies. Comparable to Lyndra's mission of enabling oral long-acting therapies, although Lilly operates at vastly greater scale and focuses on metabolic disease.
- Novo Nordisk: Novo Nordisk pioneered oral peptide delivery with Rybelsus (oral semaglutide), using a sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) absorption-enhancer platform. Comparable to Lyndra's vision of transforming chronic injectables into oral long-acting therapies, though focused on metabolic indications.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Lyndra Therapeutics social profiles
Digital presenceLyndra Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lyndra Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Lyndra Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lyndra Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lyndra Therapeutics
What does Lyndra Therapeutics do?
Lyndra Therapeutics was a clinical-stage biopharmaceutical company developing long-acting oral medicines using its proprietary LYNX drug delivery platform, which transforms standard daily pills into once-weekly or monthly oral therapies with sustained drug release. The company's lead product candidate, LYN-005, was an investigational weekly oral formulation of risperidone for the treatment of schizophrenia and other psychiatric conditions requiring long-term medication.
Is Lyndra Therapeutics a public or private company?
Lyndra Therapeutics is a private company. It is classified as venture growth investor backed and is currently closed.
When was Lyndra Therapeutics founded?
Lyndra Therapeutics was founded in 2015. It employs 51 to 100 people.
Where is Lyndra Therapeutics based?
Lyndra Therapeutics is headquartered in Watertown, United States, in the North America region.
Who are Lyndra Therapeutics's main competitors?
Direct peers on record are Tris Pharma, Osmotica Pharmaceutical and Heron Therapeutics. Broad incumbents are Catalent, Otsuka Pharmaceutical, Johnson & Johnson, Teva Pharmaceutical and Pfizer CentreOne. Emerging players are Eli Lilly and Novo Nordisk.
Does Lyndra Therapeutics have an API?
No public API is recorded for Lyndra Therapeutics.
What industry is Lyndra Therapeutics in?
Lyndra Therapeutics's product category is Long-acting oral pharmaceuticals. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLACANAB, Prescription Digital Therapeutics (PDT). Its NAICS code is 541714 and its SIC code is 2834.